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Abstract. Background: Periostin (POSTN) is a protein that
binds to integrins to support adhesion and migration of
epithelial cells. Mice lacking this gene exhibit cardiac valve
disease as well as skeletal and dental defects. Recent studies
indicated that periostin is involved in the pathogenesis and
progression of knee osteoarthritis (OA). We investigated the
influence of periostin and matrix metalloproteinases (MMPs)
on OA synoviocytes. Materials and Methods: OA patients
were classified according to the Kellgren-Lawrence system
and the levels of periostin, interleukin (IL)-4, IL-13 and
transforming growth factor-β (TGFβ) in the synovial fluid
were measured. MMPs or tissue inhibitor of MMPs (TIMPs)
with periostin in cultured cells were measured when periostin
was added to OA-associated synovial cells. Dexamethasone,
a steroid medication which shows immunosuppressive effects,
was used to investigate the influence of the downstream
cascade. Results: Periostin and IL-13 levels were up-
regulated during the progression of OA. MMP-2 and MMP-
3 levels increased in a periostin concentration-dependent
manner. Increase in MMP-2 and MMP-3 levels was inhibited
by dexamethasone treatment. Conclusion: In vivo results
herein indicate that IL-13 may induce periostin production in
OA. Furthermore, periostin may facilitate MMP production
in OA-associated synovial cells.
Osteoarthritis (OA) is the most prevalent form of joint disease,
where OA symptoms affect 5% of adults aged over 60 years
worldwide (1). It is estimated that 10% of men and 18% of
women aged over 60 years have symptomatic OA, where 80%
experience movement limitations and 25% are unable to
perform normal daily activities (2). The prevalence of OA is
rising due to increased life expectancy and risk factors such
as obesity (1). It is evident that the inflammatory response is
a key contributor to the development and progression of knee
OA (3). OA is characterized by articular cartilage damage,
low-grade synovial inflammation and hypertrophic bone
changes, which lead to functional deterioration (1). Signaling
pathways involving growth factors and cytokines are being
investigated to facilitate the development of new therapies that
target the underlying biological processes causing the disease.
This concept of ‘molecular orthopaedics’ should allow more
patient-centred diagnostic and treatment strategies.
The main symptom of OA is pain, which is also the
leading factor that makes patients change their lifestyle and
seek medical intervention (4). According to the OA Research
Society International, the objectives of OA management are
to reduce pain and inflammation, slow cartilage degradation,
improve function and reduce disability (5). Therefore,
important issues in OA treatment is discovering OA’s early
stage mediator and elucidating the underlying intracellular
signal transduction pathway. 
Periostin is a member of the fasciclin family of proteins
based on its homology with fasciclin I, which was initially
identified in insects (6). Periostin, also known as osteoblast-
specific factor 2, is a 93.3-kDa secreted, vitamin K-dependent,
glutamate-containing matricellular protein, originally isolated
from a mouse osteoblast cell line (7, 8). This protein has
known functions in osteology, tissue repair, oncology,
cardiovascular and respiratory systems and various
inflammatory settings. According to recent reports, periostin
deposition promotes chronic allergic inflammation by
activating nuclear factor kappa B (NF-ĸB) signaling (9-11).
Periostin is considered to be an important structural mediator
by balancing appropriate versus inappropriate tissue adaptation
in response to insult/injury. Certain studies have shown that
periostin is up-regulated in OA tissues (12-14). Previously, we
reported that the periostin levels in synovial fluid were up-
regulated during the progression of OA in vivo, while in vitro
experiments using human fibroblast-like synoviocytes
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suggested that addition of periostin mediated increased matrix
metalloproteinase (MMP)-9 production (15). These results
indicate that periostin secretion is related to OA tissue
remodelling. However, arthrosis synovia includes
chondrocytes and adipocytes as well as fibroblasts. In our
previous study, we used fibroblasts so the results did not
reflect the reaction of the whole synovial tissue. In addition,
the paracrine effect of periostin in OA-synoviocyte biology
remains poorly understood. 
Therefore, in this study, we re-investigated the production
of periostin as well as the cytokines that affect its production
in the synovial fluid of the knee in OA patients. Furthermore,
we evaluated the influence of periostin on OA-related
extracellular matrix modulators (16, 17) in synovial tissue
cells isolated from the knees of OA patients.
Materials and Methods
Patients. Synovial fluid was collected from 53 OA patients (mean
age, 76.3±3.9 years; age range, 68-84 years) who underwent
medical examinations at Showa University Fujigaoka Hospital
(Yokohama, Japan). The Institutional Review Board at our teaching
hospital approved the study protocol (authorization number: 2148)
and signed informed consent was obtained from all subjects before
their participation in the study. Radiographs were reviewed to
determine the size and stage of progression for the OA lesions.
Radiographic findings were classified according to the Kellgren–
Lawrence system (18), as follows: grade 1 (n=14), doubtful joint
space narrowing (JSN) and possible osteophytic lipping; grade 2
(n=15), presence of definite osteophytes and possible JSN on
anteroposterior weight-bearing radiograph; grade 3 (n=11), multiple
osteophytes, definite JSN, sclerosis, possible bony deformities; and
grade 4 (n=13), large osteophytes, marked JSN, severe sclerosis and
definite bony deformities. 
Reagents. Periostin (recombinant human periostin/OSF-2, CF) was
purchased from R&D Systems Inc. (Minneapolis, MN, USA) and
dissolved in Synoviocyte Growth Medium (M2700-HS; Articular
Engineering, Northbrook, IL, USA), which was sterilized by passing
through 0.2 μm pore filters, and stored at 4˚C until use.
Dexamethasone was purchased from Wako Pure Chemical Ind. Ltd
(Osaka, Japan). Dexamethasone was diluted in ethanol in stock
solutions at 10 mM according to the instructions of the attached
manual and stored in a freezer at −20˚C (19).
Synoviocyte culture. Human cryopreserved synoviocytes from an OA
donor (CDD-H-2910-OA) were purchased from Articular Engineering
(Northbrook, IL, USA). The OA synoviocytes re-suspended at a
density of 2×105 cells/ml in culture medium, before incubated with
0.01, 0.1 and 0.5 μg/ml periostin in combination with/without
dexamethasone (final concentration; 100 nM) in 24-well plates in
triplicates. The culture supernatants were collected for cytokines
production test after 24 h and stored at −80˚C until use. The cells also
were collected to extract the total RNA extraction after 12h.
Collection of synovial fluid. Synovial fluid was collected from OA
patients using an 18-gauge needle and then stored at −80˚C until it
was assayed.
Assay for biologically-active substances. The periostin levels in
synovial fluid were measured using a commercially available
enzyme-linked immunosorbent assay (ELISA) kit (catalogue
number: EK-074-41; Phoenix Pharmaceuticals, Inc., Burlingame,
CA, USA). The concentrations of the inflammatory cytokines,
interleukin (IL)-4 and IL-13, and transforming growth factor β1
(TGF-β1) in synovial fluid were measured using commercially
available ELISA test kits (catalogue numbers: D4050, D1300B, and
DB100B; R&D Systems, Inc., Minneapolis, MN, USA) according
to the manufacturer’s instructions. In addition, the concentrations of
MMP-1, MMP-2, MMP-3, MMP-13, tissue inhibitor of MMP
(TIMP)-1, and TIMP-2 in the culture supernatants were measured
using commercially available ELISA test kits (DMP100, MMP200,
DMP300, DM1300, DTM100, and DTM200; R&D Systems, Inc.)
according to the manufacturer’s instructions. The minimum
detectable levels for these ELISA kits were 0.14 ng/ml for human
periostin, 10 pg/ml for human IL-4, 57.4 pg/ml for human IL-13,
15.4 pg/ml for human TGF-β1, 0.006 ng/ml for human MMP-1,
0.082 ng/ml for human MMP-2, 0.045 ng/ml for human MMP-3,
3.1 pg/ml for human MMP-13, 0.08 ng/ml for human TIMP-1 and
0.004 ng/ml for human TIMP-2.
PCR primers and reagent kits. The reagents used for mRNA
isolation (TaqMan Gene Expression Cells-to-Ct™) and real-time
reverse transcription (RT)-PCR (TaqMan Gene Expression Assays)
were purchased from Applied Biosystems (Foster City, CA, USA).
These assays were performed according to the manufacturer’s
instructions (20). To compare the gene expression levels by real-time
RT-PCR, we selected MMP2 (TaqMan Gene Expression Assays;
Assay ID: Hs01548727_m1) and MMP3 (TaqMan Gene Expression
Assays; Assay ID: Hs00968305_m1). 18s, 18S ribosomal RNA
(TaqMan Gene Expression Assays; Assay ID: Hs99999901_s1), was
used as a housekeeping gene to normalize RNA loading.
mRNA isolation and quantitative RT-PCR. Total RNA was isolated
from synovial cells using 50 μl of Lysis Solution (P/N4383583).
Each total RNA sample was subjected to RT using 20× RT Enzyme
Mix (P/N 4383585) and 2× RT Buffer (P/N43833586) with an
Applied Biosystems 2720 Thermal Cycler (Applied Biosystems).
After the RT reaction, the cDNA templates were amplified by PCR
using TaqMan Gene Expression Assays, PCR primers, and RT
Master Mix (P/N 4369016). Predesigned and validated gene-specific
TaqMan Gene Expression Assays (16, 17) obtained from Applied
Biosystems were used in duplicate for quantitative RT-PCR
according to the manufacturer’s protocol. The PCR assays were
performed as follows: denaturation for 10 min at 95˚C, 40 cycles of
denaturation at 95˚C for 15 s, and annealing and extension at 60˚C
for 1 min. Samples were analysed using an ABI Prism 7900HT Fast
Real-Time PCR System (Applied Biosystems) (21, 22). Relative
quantification (23) was performed using the collected data
(threshold cycle numbers, referred to as Ct) with an ABI Prism
7900HT Sequence-Detection System (SDS) software 2.3 (Applied
Biosystems).
Statistical analysis. The data were expressed as means±standard
deviations. All of the assays were repeated three times to ensure
reproducibility. Significant differences between the control and
experimental groups were analysed by one-way analysis of variance
followed by the Scheffe test. A probability (p) value <0.05 was
considered significantly different.
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Results
Analysis of biologically active substances in synovial fluid.
Samples of synovial fluid were analyzed to determine
possible correlations between the OA grade and periostin
concentration. As shown in Figure 1, the periostin
concentration increased significantly with OA progression.
Next, we examined the levels of cytokines and TGF-β1 in
synovial fluid samples. Figure 2A shows that the IL-13
levels increased significantly in the samples with the
progression of knee OA. As shown in Figure 2B and 2C,
there were no significant differences in the IL-4 and TGF-
β1 levels in each stage of OA.
Analysis of biologically-active substances in culture
supernatants. Next, we evaluated the association of periostin
levels with the OA-related proteins MMP-1, MMP-2, MMP-
3, MMP-13, TIMP-1 and TIMP-2 in synovial cell. As shown
in Figure 3, the MMP-2 and MMP-3 levels increased in a
concentration-dependent manner to the periostin levels (Figure
3B and C). However, there were no significant differences in
the MMP-1, MMP-13, TIMP-1 and TIMP-2 levels among
groups (Figure 3A and D, Figure 4A and B). In addition, as
shown in Figure 5, the periostin-dependent increase of MMP-
2 and MMP-3 levels was inhibited by treatment with 100 nM
dexamethasone which was adjusted to concentration inhibiting
spontaneous production of MMP-2 or -3 (19).
Effects of periostin on the mRNA expression levels of MMP-
2 and MMP-3. Finally, we determined whether the addition
of periostin affected the MMP-2 and MMP-3 mRNA
expression levels in synovial cells. As shown in Figure 6A
and B, periostin significantly increased the mRNA expression
levels of MMP-2 and MMP-3 in a dose-dependent manner in
the cultured synovial cells. In addition, the periostin-
dependent increases in the MMP-2 and MMP-3 mRNA levels
were inhibited by 100 nM dexamethasone (Figure 6C and D).
Discussion
OA is defined as a disorder where changes in the form and
function of joints occur due to regressive changes and
hyperplastic changes in the joint constituent tissue. OA is one
of the most important reasons for orthopaedic surgery. The
characteristic clinical symptoms of knee OA are gradual and
progressive pain, joint swelling, and dysfunction, but aching
pain is the most common complaint. It is considered that these
clinical symptoms may be caused by tissue remodeling, such
as degeneration and the loss of joint cartilage caused by
ageing or immunological/biochemical changes.
Periostin, originally referred to an osteoblast-specific
factor 2, is an ECM protein with a size of 93.3 kDa (24),
which belongs to the fasciclin family according to its
homology with fasciclin 1. Periostin was originally isolated
from a mouse osteoblast cell line (7, 8) and it has known
functions in osteology, tissue repair, oncology, cardiovascular
and respiratory systems, and various inflammatory settings.
Periostin is characterized as a conventional ECM protein,
which is important for the maintenance of organ/tissue
structures and for the generation of fibrosis. In addition,
periostin is characterized as a matricellular protein, which
binds to its receptor, αv integrin, on the cell surface and
modulates cell functions (25). For example, intracellular
signaling involving periostin appears to enhance osteoblast
differentiation and bone formation via Wnt/β-catenin
signalling (26).
Previously, we reported that periostin (which is considered
to play an important role in the induction of tissue
remodelling) was up-regulated in the synovial fluid of OA
patients during the progression of OA in vivo. On the other
hand, in vitro experiments using human fibroblast-like
synoviocytes suggested that periostin may mediate an up-
regulation in MMP-9 (15). Consequently, periostin may play
an important role in the onset and progress of knee OA.
Even though, extensive research has helped elucidate the
function of periostin, its mode of action in OA remains
unknown. Therefore, the aim of the present study was to
analyze any effect of periostin in synovial fluid and OA
synoviocytes. First, we measured the periostin levels in
synovial fluid obtained from the knees of OA patients, which
indicated that the periostin levels increased in the synovial
fluid with the progression of osteoclasia in OA (Figure 1).
In addition, the concentration of the inflammatory cytokine
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Figure 1. Periostin concentrations in synovial fluid. Correlations
between OA grade and periostin levels in synovial fluid: grade 1 (n=14),
doubtful joint space narrowing (JSN) and possible osteophytic lipping;
grade 2 (n=15), the presence of definite osteophytes and possible JSN
on anteroposterior weight-bearing radiograph; grade 3 (n=11), multiple
osteophytes, definite JSN, sclerosis, possible bony deformities; and grade
4 (n=13), large osteophytes, marked JSN, severe sclerosis, and definite
bony deformities. Asterisks indicate significant differences (**p<0.01 vs.
grade 1). Error bars denote±standard deviation.
IL-13 increased in synovial fluid during the progression of
OA (Figure 2A). However, there were no significant
differences at the IL-4 and TGF-β1 levels during each stage
of OA (Figure 2B and C). IL-4 and IL-13 are immune-
regulatory cytokines, which are predominantly secreted by
activated Type-2 helper T (TH2) cells. 
Some studies have shown that periostin is a downstream
molecule of IL-4 or IL-13, which are highly expressed
cytokines in allergic diseases (27). Unlike IL-4, IL-13 does
not appear to be important during the initial differentiation of
CD4+ naive T-cells into TH2 cells because there are no
functional IL-13 receptors on human T cells (28-30). Instead,
IL-13 is related to the fibrosis of lesion tissue in various types
of chronic inflammation because IL-13 receptors are
expressed on endothelial cells, fibroblasts and smooth muscle
cells. TGF-β1 interacts with a number of cartilage
extracellular matrix (ECM) proteins and facilitates the
regeneration of cartilage. Our results support previous reports
that many OA patients harbor gene aberrations in a crucial
modulator of TGF-β1, asporin (ASPN) (31). The up-regulation
of periostin and IL-13 in the synovial fluid of OA patients
indicate that they may contribute to the progression of OA. 
In addition, in some types of cells, periostin reportedly
induces the expression of MMP family members (13, 14). This
induction and expression of matrix-degrading enzymes may
function in tissues containing periostin, which is formed
temporarily at the sites of damage to promote remodeling of
the original tissue. However, the paracrine effect of periostin
as a matricellular protein remains poorly understood in OA of
the knee. Our previous in vitro studies of human fibroblast-like
synoviocytes suggest that elevated periostin levels mediate
increases in the concentration of MMP-9 (15). Several studies
have reported increases in the MMP-9 expression levels in
knee synovial fluid during the progression of OA (32, 33). The
present study showed that the capacity of OA-associated
synovial cells to produce MMP-2 and MMP-3 was enhanced
by periostin stimulation (Figure 3A and B). However, periostin
did not increase the levels of TIMP (Figure 4). MMPs
comprise a family of 23 zinc-dependent endopeptidases, which
collectively degrade essentially all the components of the
extracellular matrix (34). When we looked at knee OA from a
biological viewpoint, the breakdown of cartilage matrix and
cartilage degeneration caused by chondrocyte apoptosis were
found in knee OA. MMP seems to play an essential role in the
breakdown of cartilage matrix, where nitric oxide may be
involved in chondrocyte apoptosis (35). TIMP is the natural
endogenous inhibitor of MMPs and it can inhibit all MMPs in
vitro (36). Thus, the relative balance between MMPs and
TIMPs is thought to play an essential role in tissue
development, morphogenesis, reproduction, and remodeling
(37). In this study, periostin did not change TIMP secretion, so
MMP/TIMP were dependent on MMP secretion. Furthermore,
MMP-3 is a broad-spectrum proteinase with important
regulatory functions, including the activation of other MMPs
(38). Previous studies have consistently detected elevated
levels of MMP-3 in the synovial fluid of patients with rotator
cuff tears. Gotoh et al. suggested that the endogenous MMP-3
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Figure 2. Periostin-related cytokine concentrations in synovial fluid.
Cytokines known to promote periostin production in synovial fluid were
examined. (A) IL-4 concentrations in synovial fluid. (B) IL-13
concentrations in synovial fluid. (C) TGF-β1 concentrations in synovial
fluid. Grade 1 (n=14), doubtful joint space narrowing (JSN) and
possible osteophytic lipping; grade 2 (n=15), presence of definite
osteophytes and possible JSN on anteroposterior weight-bearing
radiograph; grade 3 (n=11), multiple osteophytes, definite JSN,
sclerosis, possible bony deformities; and grade 4 (n=13), large
osteophytes, marked JSN, severe sclerosis and definite bony deformities.
Asterisks indicate significant differences (*p<0.05; **p<0.01 vs. grade
1, n.s., no significant difference). Error bars denote±standard deviation.
activity may have an important role in rotator cuff tears,
thereby indicating the possibility of a drug therapy that
specifically targets MMP-3 after rotator cuff repair to prevent
retearing after surgery (39). Thus, the depression of periostin
reaction may inhibit joint destruction by MMPs. Therefore, we
examined the levels of MMP in OA when using a pan-
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Figure 3. Concentrations of biologically-active substances in culture supernatants. We examined whether addition of periostin changed the MMP-
2 and MMP-3 production levels in cultured synovial cells. (A) MMP-1 production by cultured synovial cells. MMP-2 production by cultured synovial
cells. (B) MMP-3 production by cultured synovial cells. MMP-13 production by cultured synovial cells. (C) TIMP-1 production by cultured synovial
cells. (D) TIMP-2 production by cultured synovial cells. Asterisks indicate significant differences (**p<0.01 vs. control, n.s.: no significant
difference). Error bars denote±standard deviation.
Figure 4. Concentrations of biologically-active substances in culture supernatants. TIMP-1 and TIMP-2 levels in synovial cell cultures following
treatment with periostin (A) TIMP-1 production by cultured synovial cells. (B) TIMP-2 production by cultured synovial cells. n.s., No significant
difference, error bars denote±standard deviation.
immunosuppressive agent, dexamethasone, which inhibited the
induction of MMP-2 and MMP-3 by periostin in OA
synoviocytes (Figure 5). Our results indicate that periostin
contributes to the worsening of clinical conditions in OA. Thus,
periostin is an important candidate factor that enhances matrix
degeneration in chondrocytes via MMP-2 and MMP-3.
Dexamethasone has anti-inflammatory effects and it is
possible that its injection into the knee joint of patients with
knee OA may inhibit MMP production from joint-derived
synovial cells due to periostin stimulation, but it may also
damage the cells that make up the joint, as well as regulating
the development of joint pain. In our final experiment, we
examined the effects of the mRNA expression levels of MMP-
2 and MMP-3 on OA synoviocytes. Periostin increased the
mRNA expression levels of MMP-2 and MMP-3, but they
were inhibited by dexamethasone (Figure 6). MMPs play an
important role in the ECM because they degrade collagen and
proteoglycans in both healthy and diseased patients (40).
MMP-3 is viewed as a key regulator of ECM degeneration
and remodeling in normal tissue, and Jones et al. claimed that
its down-regulation limits MMP activation within tissues (41). 
In the context of disease pathogenesis, the expression of
MMP and TIMP must be interpreted with respect to the
proteolytic consequences of increased MMP/ TIMP ratios
(42, 43). Thus, we speculate that the up-regulation of
periostin in synovial fluid of the knee in OA may confer a
cytoprotective effect to promote tissue repair, and we propose
that periostin is a novel biomarker of knee OA progression.
Moreover, the intra-articular injection of glucocorticosteroids,
such as dexamethasone, is a conventional treatment for OA,
but the knees of OA patients injected intra-articularly with
steroids sometimes exhibit articular surface destruction, i.e.
steroid-induced arthropathy (steroid arthropathy) (44). The
principle of steroid-induced arthropathy has not been
in vivo 31: 69-78 (2017)
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Figure 5. Concentrations of MMP-2 and MMP-3 in culture supernatants with dexamethasone (dexa). Addition of dexamethasone decreased
periostatin-mediated MMP-2 and MMP-3 production levels in cultured synovial cells. (A) Effect of the dexamethasone on spontaneous productivity
of MMP-2. (B) Effect of the dexamethasone on spontaneous productivity of MMP-3. (C) Suppression efficacy of dexamethasone for periostin’s
MMP-2 production on synovial cells. (D) Suppression efficacy of dexamethasone for periostin’s MMP-3 production on synovial cells. Asterisks
indicate significant differences (**p<0.01). Error bars denote±standard deviation.
elucidated in detail, but steroid therapy is very effective as a
treatment of acute OA (44, 45, 46). However, steroid
treatment should be used with care in terms of time, niche,
and optimum dose. Intra-articular periostin may be employed
to determine whether steroid treatment is appropriate. The
results of the present study demonstrate that periostin has an
important role in the development of OA and our findings
suggest that periostin in OA may reflect tissue changes in this
chronic degenerative disease. In conclusion, we found that
IL-13 and periostin expression is associating with knee OA
disease progression. We also inferred that periostin can
facilitate MMP production by OA-associated synovial cells
and dexamethasone can control the excessive remodeling of
joints induced by periostin.
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